182 related articles for article (PubMed ID: 16204069)
21. Risk prediction of gastric cancer by analysis of aberrant DNA methylation in non-neoplastic gastric epithelium.
Tahara T; Arisawa T; Shibata T; Wang FY; Nakamura M; Sakata M; Nagasaka M; Takagi T; Kamiya Y; Fujita H; Nakamura M; Hasegawa S; Iwata M; Takahama K; Watanabe M; Hirata I; Nakano H
Digestion; 2007; 75(1):54-61. PubMed ID: 17438355
[TBL] [Abstract][Full Text] [Related]
22. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
[TBL] [Abstract][Full Text] [Related]
23. Detection of hypermethylated genes in tumor and plasma of cervical cancer patients.
Yang HJ; Liu VW; Wang Y; Chan KY; Tsang PC; Khoo US; Cheung AN; Ngan HY
Gynecol Oncol; 2004 May; 93(2):435-40. PubMed ID: 15099958
[TBL] [Abstract][Full Text] [Related]
24. Polymorphism in folate- and methionine-metabolizing enzyme and aberrant CpG island hypermethylation in uterine cervical cancer.
Kang S; Kim JW; Kang GH; Park NH; Song YS; Kang SB; Lee HP
Gynecol Oncol; 2005 Jan; 96(1):173-80. PubMed ID: 15589597
[TBL] [Abstract][Full Text] [Related]
25. Prognostic implication of aberrant promoter hypermethylation of CpG islands in adenocarcinoma of the lung.
Kim YT; Park SJ; Lee SH; Kang HJ; Hahn S; Kang CH; Sung SW; Kim JH
J Thorac Cardiovasc Surg; 2005 Nov; 130(5):1378. PubMed ID: 16256792
[TBL] [Abstract][Full Text] [Related]
26. CpG island methylation of genes accumulates during the adenoma progression step of the multistep pathogenesis of colorectal cancer.
Kim YH; Petko Z; Dzieciatkowski S; Lin L; Ghiassi M; Stain S; Chapman WC; Washington MK; Willis J; Markowitz SD; Grady WM
Genes Chromosomes Cancer; 2006 Aug; 45(8):781-9. PubMed ID: 16708352
[TBL] [Abstract][Full Text] [Related]
27. Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 Ovarian cancer cell lines.
Imura M; Yamashita S; Cai LY; Furuta J; Wakabayashi M; Yasugi T; Ushijima T
Cancer Lett; 2006 Sep; 241(2):213-20. PubMed ID: 16303245
[TBL] [Abstract][Full Text] [Related]
28. Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in human breast cancer.
Li SY; Rong M; Iacopetta B
Oncol Rep; 2006 Jan; 15(1):221-5. PubMed ID: 16328059
[TBL] [Abstract][Full Text] [Related]
29. High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors.
Wilcox CB; Baysal BE; Gallion HH; Strange MA; DeLoia JA
Cancer Genet Cytogenet; 2005 Jun; 159(2):114-22. PubMed ID: 15899382
[TBL] [Abstract][Full Text] [Related]
30. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells.
Robert MF; Morin S; Beaulieu N; Gauthier F; Chute IC; Barsalou A; MacLeod AR
Nat Genet; 2003 Jan; 33(1):61-5. PubMed ID: 12496760
[TBL] [Abstract][Full Text] [Related]
31. Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women.
Rathi A; Virmani AK; Schorge JO; Elias KJ; Maruyama R; Minna JD; Mok SC; Girard L; Fishman DA; Gazdar AF
Clin Cancer Res; 2002 Nov; 8(11):3324-31. PubMed ID: 12429618
[TBL] [Abstract][Full Text] [Related]
32. CpG island methylator phenotype (CIMP) in cancer: causes and implications.
Teodoridis JM; Hardie C; Brown R
Cancer Lett; 2008 Sep; 268(2):177-86. PubMed ID: 18471961
[TBL] [Abstract][Full Text] [Related]
33. CpG island methylator phenotypes in aging and cancer.
Toyota M; Issa JP
Semin Cancer Biol; 1999 Oct; 9(5):349-57. PubMed ID: 10547343
[TBL] [Abstract][Full Text] [Related]
34. Polymorphisms in methyl-group metabolism genes and risk of sporadic colorectal cancer with relation to the CpG island methylator phenotype.
Karpinski P; Myszka A; Ramsey D; Misiak B; Gil J; Laczmanska I; Grzebieniak Z; Sebzda T; Smigiel R; Stembalska A; Sasiadek MM
Cancer Epidemiol; 2010 Jun; 34(3):338-44. PubMed ID: 20381446
[TBL] [Abstract][Full Text] [Related]
35. Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors.
Paz MF; Avila S; Fraga MF; Pollan M; Capella G; Peinado MA; Sanchez-Cespedes M; Herman JG; Esteller M
Cancer Res; 2002 Aug; 62(15):4519-24. PubMed ID: 12154064
[TBL] [Abstract][Full Text] [Related]
36. Aberrant gene promoter methylation in plasma cell dyscrasias.
Martin P; Garcia-Cosio M; Santon A; Bellas C
Exp Mol Pathol; 2008 Jun; 84(3):256-61. PubMed ID: 18410922
[TBL] [Abstract][Full Text] [Related]
37. Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progression.
Keita M; Wang ZQ; Pelletier JF; Bachvarova M; Plante M; Gregoire J; Renaud MC; Mes-Masson AM; Paquet ÉR; Bachvarov D
Gynecol Oncol; 2013 Feb; 128(2):356-63. PubMed ID: 23219462
[TBL] [Abstract][Full Text] [Related]
38. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes.
Strathdee G; Appleton K; Illand M; Millan DW; Sargent J; Paul J; Brown R
Am J Pathol; 2001 Mar; 158(3):1121-7. PubMed ID: 11238060
[TBL] [Abstract][Full Text] [Related]
39. Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential.
Wiley A; Katsaros D; Chen H; Rigault de la Longrais IA; Beeghly A; Puopolo M; Singal R; Zhang Y; Amoako A; Zelterman D; Yu H
Cancer; 2006 Jul; 107(2):299-308. PubMed ID: 16773633
[TBL] [Abstract][Full Text] [Related]
40. Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data.
Yang HJ; Liu VW; Wang Y; Tsang PC; Ngan HY
BMC Cancer; 2006 Aug; 6():212. PubMed ID: 16928264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
